Endologix, Inc. (ELGX) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Endologix, Inc. (NASDAQ:ELGX) have been assigned a consensus recommendation of “Hold” from the twelve analysts that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and one has given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $5.36.

ELGX has been the topic of a number of recent research reports. BidaskClub downgraded Endologix from a “buy” rating to a “hold” rating in a report on Friday, December 15th. Canaccord Genuity reaffirmed a “hold” rating and set a $5.00 price objective on shares of Endologix in a report on Wednesday, November 8th. Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Endologix in a report on Tuesday, December 12th. Zacks Investment Research downgraded Endologix from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Finally, Stifel Nicolaus decreased their price objective on Endologix from $6.00 to $5.50 and set a “hold” rating on the stock in a report on Wednesday, November 8th.

Large investors have recently bought and sold shares of the company. Alliancebernstein L.P. raised its stake in shares of Endologix by 11.5% in the second quarter. Alliancebernstein L.P. now owns 108,757 shares of the medical instruments supplier’s stock valued at $529,000 after acquiring an additional 11,200 shares during the last quarter. Swiss National Bank raised its stake in shares of Endologix by 14.3% in the second quarter. Swiss National Bank now owns 137,900 shares of the medical instruments supplier’s stock valued at $670,000 after acquiring an additional 17,300 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Endologix by 10.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 321,309 shares of the medical instruments supplier’s stock valued at $1,562,000 after acquiring an additional 30,429 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Endologix by 211.2% in the third quarter. JPMorgan Chase & Co. now owns 109,380 shares of the medical instruments supplier’s stock valued at $488,000 after acquiring an additional 74,227 shares during the last quarter. Finally, Teachers Advisors LLC raised its stake in shares of Endologix by 40.8% in the second quarter. Teachers Advisors LLC now owns 198,912 shares of the medical instruments supplier’s stock valued at $967,000 after acquiring an additional 57,675 shares during the last quarter.

Shares of Endologix (NASDAQ ELGX) opened at $4.21 on Tuesday. The company has a debt-to-equity ratio of 2.61, a quick ratio of 2.11 and a current ratio of 2.90. The firm has a market capitalization of $344.66, a P/E ratio of -4.53 and a beta of 0.42. Endologix has a 1-year low of $4.00 and a 1-year high of $7.66.

ILLEGAL ACTIVITY WARNING: “Endologix, Inc. (ELGX) Receives Consensus Recommendation of “Hold” from Brokerages” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/13/endologix-inc-elgx-receives-consensus-recommendation-of-hold-from-brokerages.html.

About Endologix

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply